The company’s first product, the CyMedica QB1™ system for the treatment of quadriceps muscle atrophy, was first shown at the AAOS meeting in March 2015. In April 2015, it received 510(k) clearance and was launched at the Arthroscopy Association of North American Arthroscopic Society for Sports Medicine (AANA) annual meeting in Los Angeles. Since launch, surgeons and patients have received the QB1 system enthusiastically across the United States.
The CyMedica QB1 allows the surgeon to combine three best-in-class products to allow the orthopedic surgeon to treat “every” patient like a professional athlete: a postoperative knee brace, a form-fitting conductive garment, and a user-friendly NMES control interface. The QB1 technology utilizes the first closed-loop power control system delivering high intensity electrical muscle stimulation to patients while maintaining comfort. The device substantially simplifies the delivery of at-home NMES treatment and encourages patient compliance.
“This successful round of financing will enable us to expand our sales and distribution footprint and further support the continued rollout of our QB1 System,” said Rob Morocco, President and CEO of CyMedica Orthopedics. “We're excited to have the backing of an excellent group of strategic investors supporting us in building the organization and expanding the applications of our platform technology.”
For more information on the CyMedica Orthopedics QB1 please visit www.cymedicaortho.com.
Based in Scottsdale, Arizona, CyMedica Orthopedics is a privately held medical device company that develops and commercializes innovative products that target muscle atrophy using its patented platform technology. That technology includes the first closed-loop power control system to provide patients comfortable yet aggressive treatment.
Source CyMedica Orthopedics ©
Aucun commentaire:
Enregistrer un commentaire